abiraterone,prednisone,niraparib
janssen
['prostate', 'crpc', 'magnitude study', 'janssen']
metastatic castration-resistant prostate cancer (mcrpc) carries a poor prognosis. we are taking a patient-centric approach to understand potential treatments with better outcomes. learn more about our latest data in the magnitude study at #ascogu2023: 
Official Twitter site of JanssenUS, to inform media about company news.  Tweets by our communications team. Review our guidelines here: https://t.co/WrVM19L6Yn